Emerging Markets Report: Love Letters
Mindset Pharma Inc. (OTCQB: MSSTF) recently communicated positive developments to shareholders, emphasizing two key points. First, the partnership with MSRD, part of Otsuka's global pharmaceutical network, validates Mindset's approach to psychedelic drug development and secures ongoing funding. Second, the company aims to develop a diverse pipeline of psilocybin-inspired drug candidates, potentially leading to commercialization and increased revenue. Overall, Mindset's letter reflects a strong commitment to advancing its therapeutic portfolio and enhancing shareholder relations.
- Partnership with MSRD validates Mindset's drug development approach.
- Secures ongoing funding for future projects.
- Intention to create a diverse pipeline for commercialization and potential revenue growth.
- None.
An Emerging Markets Sponsored Commentary
ORLANDO, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- In the world of emergent small cap companies there are a few things we love to see. Chief among them are positive shareholder letters from senior management.
And that’s exactly what shareholders of Mindset Pharma Inc. (Mindset) (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF), a drug discovery and development company focused on creating next-generation psychedelic medicines to treat neurological and psychiatric disorders, just got.
Here it is but give us just a minute before you click over.
Shareholder letters can have a unique effect. Positive shareholder letters are usually a window into a Company’s self-belief that there are positive developments and/or things are otherwise going well and to share such developments with its investors.
In the case of Mindset’s recent offering we believe it’s very clear that CEO James Lanthier wants to hammer home two points as indicated by its introductory titles.
Let’s take a look at both points.
First, point one:
MSRD Partnership Validates Mindset’s Psychedelic Drug Development Approach and Provides Ongoing Funding
Lanthier is explicitly clear that this agreement is transformative not just for Mindset, but also perhaps for the psychedelic industry and eventually helping patients achieve happier lives and better therapeutic outcomes using psychedelics. MSRD is a member of the global Otsuka family of pharmaceutical companies, a giant pharmaceutical company with massive capability and influence. The fact that Mindset is inside their big tent should not be overlooked. As Lanthier eloquently calls it, “a bridge from traditional Big Pharma to the new emerging world of psychedelic medicine.”
Mindset is helping to build that bridge.
Development Platform Enables Multiple Clinical Opportunities for a Variety of Modalities
Here’s the line that is paramount for us:
“…we continue to evaluate and collect a strong critical data package for our psilocybin-inspired Families 1 and 3 drug candidates.”
This may be the beginnings of what could be a drug pipeline for Mindset. This is drug development so there are many, many rungs in the ladder toward commercialization but what should be noted here is that the there is a stated intention to create a portfolio of therapeutics. More products can equal more commercialization and more potential revenue.
Mindset’s letter suggests that the Company is in a very good place and that it wants to make sure that its shareholders know it.
About The Emerging Markets Report:
The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stockbrokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.
For more informative reports such as this, please sign up at https://emergingmarketsconsulting.com/
Must Read OTC Markets/SEC policy on stock promotion and investor protection
- https://www.otcmarkets.com/learn/policy-on-stock-promotion
- https://www.otcmarkets.com/learn/investor-protection
- https://www.sec.gov/news/press-release/2017-79
- https://www.sec.gov/oiea/investor-alerts-bulletins/ia_promotions.html
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
EMC has been paid
Emerging Markets Consulting, LLC
Florida Office
390 North Orange Ave STE 2300
Orlando, FL 32801
E-mail: jamespainter@emergingmarketsllc.com
Web: https://emergingmarketsconsulting.com/
FAQ
What is the significance of Mindset Pharma's partnership with MSRD?
What are Mindset Pharma's plans for drug development?
How does Mindset Pharma communicate with its shareholders?
What is Mindset Pharma's stock symbol?
